bpc-157 myelin JPP No 5/2013 article 09 Stable Gastric Pentadecapeptide BPC 157
Description
Residual disability, estimated to affect 6% of neurologic patients, is the most feared outcome of cobalamin deficiency and is likely to persist if still present after 6 to 12 months of treatment

The key finding was the comparable clinical effectiveness among those four therapeutic agent groups

Preclinical work points to a mechanism centered on 3-adrenergic receptor modulation, enhanced lipolysis, and reduced lipogenesis, largely independent of the insulin- and IGF-1-related pathways associated with full-length HGH

L.BalajiS.WangX.ParikhU
